Comment: Sanofi-Maze block from US FTC lends legitimacy to early-stage pharmaceutical challenges, raises issues for future deals
The US Federal Trade Commission’s move to block Sanofi’s proposed licensing agreement with Maze Therapeutics last week — the agency’s first challenge of an unconsummated merger involving a Phase 1 pipeline...To view the full article, register now.
Already a subscriber? Click here to view full article